Fatty acids pharmacokinetics

Busnach, G. et al., Effect of n-3 polyunsaturated fatty acids on cyclosporine pharmacokinetics in kidney graft recipients A randomized placebo-controlled study, J Nephrol, 11, 87, 1998. 

H. Hasegawa, K. S. Lee, T. Nagaoka, Y. Tezuka, M. Uchiyama, S. Kadota, I. Saiki, Pharmacokinetics of Ginsenoside Deglycosylated by Intestinal Bacteria and Its Transformation to Biologically Active Fatty Acid Esters , Biol. Pharm. Bull. 2000, 23, 298 -304. 

Pharmacokinetics of ginsenoside deglycosylated by intestinal bacteria and its transformation to biologically active fatty acid esters. Biol. Pharm. Bull. 23, 298-304. 

The short chain fatty acids include butyrate derivatives Hke phenylbu-tyrate, AN-9 (pivaloyloxymethyl butyrate) and valproate. Unfortimately, these compounds have poor potency and pharmacokinetic properties, including short half-life. Numerous Phase I studies with phenylbutyrate, in various oral and intravenous schedules [118-120] have been performed, with neurological toxicity at higher doses being reported. AN-9 showed initial promise in a Phase I study, where the MTD was not reached [121]. The subsequent Phase II study in nonsmall cell lung cancer in 47 patients resulted in fatigue, nausea and dysgeusia as common toxicities. Three partial responses (PR)... 

Heparin also enhances lipoprotein lipase release (which clears plasma of circulating lipids), increases circulating free fatty acids, and reduces lipoprotein levels. Pharmacokinetics ... 

Pharmacokinetics Minimal absorption bytheGl tract. Maybe metabolized like other fatty acids. 

Mechanism of Action Afibricacid derivative that inhibits lipolysis of fat in adipose tissue decreases liver uptake of free fatty acids and reduces hepatic triglyceride production. Inhibits synthesis of VLDL carrier apolipoprotein B. Therapeutic Effect Lowers serum cholesterol and triglycerides (decreases VLDL, LDL increases HDL). Pharmacokinetics Well absorbed from the GI tract. Protein binding 99%. Metabolized in liver. Primarily excreted in urine. Not removed by hemodialysis. Half-life 1.5 hr. 

Mechanism of Action An antioxidant that prevents oxidation of vitamins A and C, protects fatty acids from aff ack by free radicals, and protects RBCs from hemolysis by oxidizing agents. Therapeutic Effect Prevents and treats vitamin E deficiency. Pharmacokinetics Variably absorbed from the GI tract (requires bile salts, dietary fat, and normal pancreatic function). Primarily concentrated in adipose tissue. Metabolized in the liver. Primarily eliminated by biliary system. 

Rats weighing 180-240 g are kept on standard diet. Groups of 8 non-fasted animals are treated orally with various doses of the test compounds suspended in 0.4% starch suspension. One control group receives the vehicle only. Blood is withdrawn from the tip of the tail immediately before, and 1,2,3,5, and 24 hours after administration of the candidate compound. Blood glucose is determined in 10 pi blood samples collected from the tip of the tail. If pharmacokinetic data for the candidate compound are already available, when performing this test, additional blood samples (100 pi) should be taken at max by retro orbital bleeding for detection of free fatty acids, triglycerides and insulin. 

The pharmacokinetics of PFOS and PFOA have been investigated in animal studies [22-24]. Results indicate that both PFCs are well absorbed following oral exposure, and poorly eliminated. In addition, PFOS and PFOA are very persistent as they are not metabolized and undergo extensive enterohepatic circulation [25,26]. PFSAs and PFCAs are unique among other persistent halogenated organic contaminants as they do not preferentially accumulate in fatty tissues, but instead are predominately distributed in the liver, serum and kidney [22-24]. This may be explained by the fact that PFOS and PFOA bind to proteins, specifically )8-lipoproteins, albumin and liver fatty acid-binding proteins [27, 28]. 

In comparison with phenytoin and carbamazepine, which induce changes in TGS of several hundred microampere, the effects of the fatty acids were rather small. However, a more conspicuous difference was the slow increase in threshold over a period of several hours. With intravenous administration of phenytoin, carbamazepine, or valproate, the maximal effect is reached almost immediately after injection, after which the threshold returns to baseline in 4—6 h. The pharmacokinetics were not investigated in detail, but the time-course of effect certainly did not follow the plasma concentration. Blood samples taken from some rats that were treated with DHA or EPA indicated that the plasma concentration was maximal at the end of the infusion and dropped to undetectable levels after 6 h (probably already after 3 h). 

As with GC, HPLC can be used qualitatively for identification or quantitatively to determine how much of a compound is present. Some examples of the use of HPLC in qualitative work include identification of impurities and toxicity screening. Some examples of the use of HPLC in quantitative work are drug testing in athletes and in sports supplements, pharmacokinetic studies of drugs pharmaceutical assays and fatty acid analysis. ... 

This increases the free fraction of cbiordiazepoxide, diazepam, iorazepam, and oxazepam. The mechanism is probably via induction by beparin of concomitant free fatty acid changes, which consequently alter benzodiazepine pharmacokinetics. 

---